Title: Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: A multi-study sub-analysis
Abstract: Objectives: Olaparib is an oral poly ADP ribose polymerase (PARP) inhibitor with documented antitumor activity among women with relapsed ovarian cancer (OC) who carry a germline BRCA1/2 mutation (gBRCAm). We sought to evaluate the pooled objective response rate (ORR), duration of response (DoR), and safety of olaparib in this patient population from completed single-agent olaparib trials.
Publication Year: 2015
Publication Date: 2015-04-01
Language: en
Type: article
Indexed In: ['crossref']
Access and Citation
Cited By Count: 3
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot